Drug Pipeline Monthly Update
|
|
- Delphia Harris
- 6 years ago
- Views:
Transcription
1 Drug Pipeline Monthly Update Critical updates in an ever changing environment June 2017 New drug information Baxdela (delafloxacin): The Food and Drug Administration (FDA) approved Melinta s Baxdela, a fluoroquinolone antibiotic, for the treatment of skin and skin structure infections caused by a range of bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). Baxdela is available both as an intravenous infusion and as an oral tablet. Symjepi (epinephrine injection): The FDA approved Adamis Symjepi, a therapeutic alternative to Mylan s EpiPen. Symjepi is available as a prefilled syringe that can be administered via intramuscular or subcutaneous routes for the emergency treatment of allergic reaction, including anaphylaxis. It is not an alternative for EpiPen Jr, but Adamis does plan to file a New Drug Application (NDA) for a junior version in the future. Adamis anticipates launch of Symjepi in the second half of 2017 at a lower cost than EpiPen. 1 Generic drug information Armour Thyroid (thyroid tab): Acella launched the first generic for Actavis Armour Thyroid for the replacement or supplemental therapy in patients with hypothyroidism. Strattera (atomoxetine): Teva, Glenmark, and Aurobindo/Rising have launched their generic versions of Eli Lilly s Strattera for the treatment of attention-deficit/hyperactivity disorder (ADHD). According to IMS, Strattera had approximately $535 million in sales over the past year. Pataday (olopatadine): Teva has launched the first generic for Novartis Pataday for the treatment of ocular itching associated with allergic conjunctivitis. Teva has 180 days of marketing exclusivity after which multiple manufactures will launch their generic versions of Pataday. According to IMS, Pataday had $303 million dollars in sales over the past year. Acticlate (doxycycline hyclate): Mayne Pharma launched their generic of Aqua Acticlate for the treatment of: rickettsial infections, sexually transmitted infections, respiratory tract infections, specific bacterial infections, ophthalmic infections, anthrax, alternative treatment to penicillin where it is contraindicated, adjunctive therapy in acute intestinal amebiasis and severe acne, and the prevention of malaria. Apotex may receive FDA approval for their generic version in Acticlate generated $250 million in U.S. annual sales over the past year. Renvela (sevelamer carbonate): Aurobindo Pharma launched their generic of Genzyme s Renvela packets for oral suspension to control serum phosphorus in patients with chronic kidney disease on dialysis. It is unclear when the FDA will grant approval to additional generic versions of Renvela packets. While the information in this newsletter is from sources we believe to be reliable, we do not warrant that the information in this document is free from error. Use it only as a guide. Statements regarding drugs or manufacturers are not intended as promotion; those statements should not be used to make assumptions about formulary status. Each trademarked drug name is the property of its respective owner.
2 Drug Pipeline Monthly Update: June 2017 Page 2 New molecular entity approvals in the past 12 months Generic name Brand name Manufacturer Indication(s) Date approved* delafloxacin Baxdela Melinta Skin infections June 2017 naldemedine Symproic Shionogi Pain March 2017 safinamide Xadago Newron Parkinson s disease March 2017 desmopressin nasal spray Noctiva Allergan and Serenity Nocturnal polyuria March 2017 house dust mite sublingual allergy immunotherapy Odactra Merck, Sharp & Dohme House dust mite allergies March 2017 plecanatide Trulance Synergy Chronic idiopathic constipation January 2017 crisaborole Eucrisa Pfizer/Anacor Mild to moderate atopic dermatitis December 2016 prasterone Intrarosa Endoceutics Inc Pain during intercourse November 2016 lixisenatide Adlyxin Sanofi Diabetes July 2016 lifitegrast Xiidra Shire Dry eye disease July 2016 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
3 Drug Pipeline Monthly Update: June 2017 Page 3 Other new product approvals in the past twelve months Generic name Brand name Manufacturer Indication(s) Date approved* epinephrine injection Symjepi Adamis Allergic reactions June 2017 Corporation methotrexate solution Xatmep Silvergate ALL and arthritis in pediatric patients April 2017 oxycodone, immediate-release RoxyBond Inspirion/Daiichi Pain with abuse-deterrent April 2017 Sankyo dapagliflozin/saxagliptin Qtern AstraZeneca Diabetes February 2016 lisdexamfetamine Vyvanse Shire ADHD (chew tab) February 2017 naloxone nasal spray, 2 mg Narcan Adapt Pharma Inc Opioid overdose January 2016 fluticasone propionate fluticasone propionate/ salmeterol ArmonAir Teva Asthma January 2016 RespiClick AirDuo RespiClick Teva Asthma January 2016 oxymetazoline Rhofade Allergan Rosacea January 2016 hydrocodone extended release Vantrela ER Teva Pain, abuse deterrent January 2016 morphine extended release Arymo ER Egalet Pain, abuse deterrent January 2016 insulin glargine Basaglar Eli Lilly Diabetes December 2015, launched in December 2016 empagliflozin/metformin Synjardy XR Eli Lilly Diabetes December 2016 extended release Lantus (insulin glargine)/ Soliqua Sanofi Diabetes November 2016 Adlyxin (lixisenatide) Tresiba (insulin degludec/ Xultophy Novo Nordisk Diabetes November 2016 Victoza (liraglutide) doxylamine/pyridoxine XR Bonjesta Duchesnay Pregnancy-related nausea and vomiting November 2016 tenofovir alafenamide Vemlidy Gilead Hepatitis B November 2016 mebendazole Vermox Johnson & Johnson/ Parasitic disease November 2016 Janssen norethindrone/estradiol fe Taytulla Apil Pregnancy prevention October 2016 sumatriptan/naproxen Treximet Permix Migraine October 2016 levonorgestrel-releasing Kyleena Bayer AG Pregnancy prevention September 2016 intrauterine system phentermine HCl Lomaira KVK Tech Weight loss September 2016 aspirin/omeprazole delayedrelease oxycodone/naltrexone extended release granisetron, extended-release injection Yosprala Aralez, Inc Secondary prevention of CV disease in patients with high risk for ASA-induced ulcers September 2016 Troxyca ER Pfizer Pain August 2016 Sustol Heron Therapeutics Prevention of chemotherapy-induced nausea and vomiting August 2016 lisinopril oral solution Qbrelis Silvergate Hypertension July 2016, Inc dronabinol Syndros Insys Therapeutics HIV wasting and chemotherapy induced nausea and vomiting in cancer patients July 2016 *Date indicates FDA approval date only. The product launch and marketing dates are determined by the approved product s manufacturer.
4 Drug Pipeline Monthly Update: June 2017 Page 4 Pipeline watch Generic name Brand name Manufacturer Indication(s) Anticipated FDA decision date ozenoxacin N/A Medimetriks Impetigo June 2017 methylphenidate ER Cotempla XR-ODT Neos Therapeutics ADHD June 2017 mixed amphetamine salts long acting betrixaban N/A Portola methylphenidate delayed and extended release N/A Shire ADHD June 2017 N/A Ironshore / Highland Therapeutics Prevention of venous thromboembolism June 2017 (VTE) ADHD July 2017 CCP-08 N/A Vernalis/ Cough and cold August 2017 Tris ITCA 650 (exenatide mini-pump) N/A Intarcia Diabetes September 2017 oxycodone controlled-release Rexista Intellipharmaceuticals Pain, abuse deterrent September 2017 fluticasone furoate/ N/A GSK/Innoviva COPD September 2017 umeclidinium/vilanterol secnidazole Solosec Symbiomix Bacterial vaginosis September 2017 amphetamine XR N/A Neos Therapeutics ADHD September 2017 lesinurad/allopurinol Duzallo Ironwood Uncontrolled gout September 2017 insulin aspart FIAsp Novo Nordisk Diabetes September 2017 cetirizine Zerviate NicOx Eye itching and inflammation September 2017 tadalafil PharmFilm N/A MonoSol RX ED September 2017 testosterone enanthate QuickShot Antares Hypogonadism October 2017 aprepitant Cinvanti Heron Therapeutics Chemotherapy-induced nausea and November 2017 vomiting semaglutide N/A Novo Nordisk Diabetes December 2017 ertugliflozin N/A Merck/Pfizer Diabetes December 2017 ertugliflozin/metformin N/A Merck/Pfizer Diabetes December 2017 ertugliflozin/sitagliptin N/A Merck/Pfizer Diabetes December 2017 acetaminophen/ibuprofen Maxigesic AFT Pain December 2017
5 Drug Pipeline Monthly Update: June 2017 Page 5 First generic approvals of top selling brand name drugs in the past twelve months Generic name Brand name Manufacturer Indication(s) Approval date* atomoxetine Strattera Eli Lilly ADHD June 2017 ezetimibe Noctiva Allergan and Serenity Nocturnal polyuria March 2017 simvastatin Vytorin Merck/ Schering-Plough High cholesterol May 2017 desvenlafaxine SR Pristiq Pfizer Depression March 2017 methylphenidate ER Concerta Janssen ADHD January 2017 oseltamivir phosphate capsules Tamiflu Roche/Genetech Influenza December 2016 ezetimibe Zetia Merck High cholesterol December 2016 olmesartan and olmesartan/hctz Benicar / Benicar HCT Daiichi-Sankyo High blood pressure November 2016 quetiapine XR Seroquel XR AstraZeneca Schizophrenia/bipolar disorder November 2016 * Date usually indicates FDA approval date. The product s launch date is determined by the manufacturer. Generic approvals that do not come to market within three months of approval are listed and dated when they enter the market.
6 Drug Pipeline Monthly Update: June 2017 Page 6 Other first generic launches in the past twelve months Generic name Brand name Manufacturer Indication(s) Date approved* olopatadine solution Pataday Teva Eye itching June 2017 thyroid tab Armour Thyroid Actavis Hypothyroid June 2017 desoximetasone ointment Topicort Taro Skin conditions May 2017 tazarotene cream Tazorac Allergan Plaque psoriasis and acne April 2017 levonorgestrel/ethinyl estradiol Quartette Teva Pregnancy prevention April 2017 venlafaxine extended-release Venlafaxine ER UCB Pharma/Vertical Depression and anxiety April 2017 zileuton extended-release Zyflo CR Chiesi USA Asthma April 2017 prednisolone sodium phosphate Millipred Zylera Inflammatory conditions March 2017 oral solution 10 mg/5 ml prednisolone sodium phosphate Veripred 20 Zylera Inflammatory conditions March 2017 oral solution 20 mg/5 ml methylphenidate SR 60 mg Ritalin LA Novartis ADHD March 2017 flurandrenolide oint Cordran Aqua Skin irritation February 2017 lopinavir/ritonavir soln Kaletra AbbVie HIV January 2017 aspirin/dipyridamole Aggrenox Boehringer Ingelheim Reduce risk of stroke January 2017 dexmethylphenidate Focalin XR Novartis ADHD January 2017 rasagiline Azilect Teva Neuroscience Parkinson s disease January 2017 aprepitant Emend Merck/Schering-Plough Chemotherapy induced nausea/ vomiting epinephrine injection, USP auto-injection Authorized generic of Epipen and Epipen Jr Auto-Injector January 2017 Mylan Anaphylaxis December 2016 bimatoprost Latisse Allergan Dermatologics Eyelash growth December 2016 armodafinil Nuvigil Cephalon Improve wakefulness in patients with November 2016 excessive sleepiness associated certain disorders fluoxetine tablets Sarafem Actavis Premenstrual dysphoric disorder November 2016 olmesartan/amlodipine/ Tribenzor Daiichi Sankyo Hypertension November 2016 hydrochlorothiazide amlodipine/olmesartan Azor Daiichi Sankyo Hypertension November 2016 hydromorphone XR Exalgo Mallinckrodt Brand Pain October 2016 Pharma Yuvafem (estradiol vaginal tab) Vagifem Novo Nordisk Vaginitis October 2016 flurandrenolide lotion Cordran Aqua Eczema October 2016 valganciclovir solution Valcyte Genetech CMV September 2016 sumatriptan nasal spray, Imitrex nasal spray Glaxo Smith Kline Migraine August mg/act and 20 mg/act ethacrynic acid Edecrin Valeant Edema August 2016 nilutamide Nilandron Concordia Metastatic prostate cancer July 2016 / Covis omeprazole/sodium bicarbonate Zegerid powder pack Valeant For treatment of duodenal ulcer, GERD July 2016 for suspension pramipexole ER Mirapex ER 3.75 mg Boehringer Ingelheim Parkinson s disease July 2016 clindamycin phosphate/tretinoin Ziana gel Valeant Acne July 2016 fenofibrate Fenoglide Valeant High cholesterol July 2016 * Date usually indicates FDA approval date. The product s launch date is determined by the manufacturer. Generic approvals that do not come to market within three months of approval are listed and dated when they enter the market.
7 Drug Pipeline Monthly Update: June 2017 Page 7 Generics of top selling brand drugs potentially available soon Generic name Brand name Manufacturer Indication(s) To market date* eletriptan Relpax Pfizer Migraines 2017 oseltamivir phosphate suspension Tamiflu Roche/Genetech Influenza 2017 moxifloxacin ophthalmic solution Vigamox Alcon/Novartis Infection July 2017 prasugrel Effient Eli Lilly/Daiichi Sankyo Heart August 2017 exenatide Byetta AstraZeneca Diabetes October 2017 sildenafil citrate Viagra Pfizer ED December 2017 tadalafil Cialis Lilly ED December glatiramer acetate 40 mg/ml Copaxone Teva Multiple sclerosis *Expected to market dates are predictions made by Prime Therapeutics based on industry information. Reference 1. All brand names are property of their respective owners A1 Prime Therapeutics LLC 06/17
Drug Pipeline Monthly Update
Drug Pipeline Monthly Update Critical updates in an ever changing environment December 2017 New drug information Juluca (dolutegravir/rilpivirine): Viiv Healthcare received U.S. Food and Drug Administration
More informationWell Informed. A Comprehensive Approach to Pain Management. Pain Guardian
Q1 2 0 1 7 Well Informed A Comprehensive Approach to Pain Management Use of opioids is common and necessary to support treatment for a wide variety of health related issues; however, the use of opioid
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective Jan. 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationPartners Notice of Change March 2017
New Added Products: Effective 3/1/2017 Drug Reason Tier Restrictions abacavir 600 mg-lamivudine 300 QL ADRENACLICK 0.15 MG/0.15 ML INJECTION,AUTO- INJECTOR ADRENACLICK 0.3 MG/0.3 ML INJECTION, AUTO- INJECTOR
More informationCURRENT STATUS ANTICIPATED APPROVAL PIPELINE DRUG WHAT IS THIS DRUG BEING DEVELOPED FOR? allopurinol / lesinurad Duzallo - Ironwood /4/2017
PIPELINE DRUG CURRENT STATUS ANTICIPATED APPROVAL WHAT IS THIS DRUG BEING DEVELOPED FOR? allopurinol / lesinurad Duzallo - Ironwood 10/4/ Fixed dose combination of Zurampic (lesinurad) and allopurinol
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationBlue Cross and Blue Shield of Minnesota GenRx Formulary Updates
Blue Cross and Blue Shield of Minnesota GenRx Formulary Updates July 2018 TRADE NAME (generic name) or generic name ADVAIR DISKUS (fluticasone-salmeterol aer powder ba 100-50 mcg/dose) Brand Addition ADVAIR
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective Jan. 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationNew Drugs of /23/2017. Disclosure. Learning Objectives: Technicians
New Drugs of 2016 Kendra Ernste, Pharm.D 2018 Candidate and Khia Warzecha, Pharm.D 2019 Candidate Disclosure We have had no financial relationship over the past 12 months with any commercial sponsor with
More informationQUANTITY LIMIT CRITERIA
DRUG CLASS (ADHD) AGENTS BRAND NAME (generic) QUANTITY LIMIT CRITERIA ATTENTION DEFICIT HYPERACTIVITY DISORDER ADDERALL (amphetamine mixture) ADDERALL XR (amphetamine extended-release mixture) ADZENYS
More informationAdded, Removed or Changed. Date of Change. No Change
One mission: you s September 7, 2017 Blue Cross of Idaho reviews its formularies (covered drug lists) periodically to allow members access to new drugs and to provide safe, cost effective options for your
More informationVIVA MEDICARE IMPORTANT T EXPANDED PERFORMANCE FORMULARY UPDATES
NORE/ETH/FER CHW 0.MG Added to the 07 //07 ALYACEN TAB / Added to the 07 //07 AMETHIA LO TAB Added to the 07 //07 ERGOT/CAFFEN TAB 00MG Added to the 07 //07 NORETH/ETHIN TAB /0 Added to the 07 //07 LORCET
More informationFacts about ADHD drugs as treatment
Facts about ADHD drugs as treatment Common ADHD drugs as treatment Medication Stimulants Methylphenidate Dexmethylphenidate Amphetamine Non-Stimulants Straterra Guanfacine ER (Intuniv) Clonidine (Kapvay)
More informationPharmacy Benefit Coverage Updates Jan. 1, 2018
Pharmacy Benefit Coverage Updates Jan. 1, 2018 UnitedHealthcare routinely evaluates prescription benefit coverage to help ensure we offer members affordable and effective medication options. Medications
More informationFORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
More informationPharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017
Pharmacy Program Updates: Quarterly Pharmacy Changes Effective July 1, 2017 DRUG LIST CHANGES Based on the availability of new prescription medications and Prime s National Pharmacy and Therapeutics Committee
More informationADHD STIMULANTS-S(SHC)
Step Therapy Simply Health Care 2014 Formulary ID: 14406 Version: 14 Last Updated: 08/01/2014 ADHD STIMULANTS-S(SHC) Daytrana Focalin Xr Strattera Patient needs to have a paid claim for one Step 1 drug
More informationSubject: HPN/SHL COMMERCIAL PDL UPDATES EFFECTIVE JANUARY 1, 2018
Date: November 7, 2017 To: From: HPN/SHL Contracted Pharmacies and Providers Ryan Bitton, PharmD, MBA Senior Director, Pharmacy Subject: HPN/SHL COMMERCIAL PDL UPDATES EFFECTIVE JANUARY 1, 2018 Effective
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These generic drugs recently became available in the marketplace. When these generic drugs became available, we began covering them at the
More informationANTICIPATED APPROVAL. Priority Review. Priority Review
PIPELINE DRUG CURRENT STATUS ANTICIPATED APPROVAL WHAT IS THE DRUG BEING DEVELOPED FOR? adapalene gel 0.1% (Differin Rxto-OTC - Galderma) July 2016 Rx-to-OTC conversion of Differin (adapalene 0.1% gel)
More informationCRITERIA Trial of two generic formulary products from the following: atomoxetine or ADHD stimulant medication.
ADHD STIMULANTS ATOMOXETINE HCL, DEXEDRINE 10 MG TABLET, DEXEDRINE 5 MG TABLET, DEXMETHYLPHENIDATE HCL, DEXMETHYLPHENIDATE HCL ER, DEXTROAMPHETAMINE 10 MG TAB, DEXTROAMPHETAMINE 5 MG TAB, DEXTROAMPHETAMINE
More informationAetna Better Health of Illinois Medicaid Formulary Updates
October 2017 o DOXYLAMINE SUCCINATE 25mg-QL o DULOXETINE CAP 40MG DR-QL o GUANFACIN ER TABS (all strengths)-ql o TOBRAMYCIN NEBU SOLUTION- PA August 2017 Aetna Better Health of Illinois Medicaid 2017 Formulary
More informationPrescribing Guide Standard Control Change Summary Report Effective (Standard Drug List Reflects Removals)
This report highlights all changes (additions, deletions and removals) to the CVS Caremark Prescribing Guide Standard Control. ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Estring (estradiol)
More informationTABLE OF CONTENTS (Click on a link below to view the section.)
Follow the links below to access the complete formularies for Plans: Health Plan Acne Allergy Allergic Anaphylactic Reaction Allergic Conjunctivitis Allergic Rhinitis Asthma Atopic Dermatitis Behavioral
More informationFORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS
FORMULARY UPDATES TO DENVER HEALTH MEDICAID CHOICE (DHMC) AND CHILD HEALTH PLAN PLUS (CHP+) PLANS DHMC/CHP+ may add or remove drugs from the formulary or make changes to restrictions on formulary drugs
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Generic Additions These generic drugs recently became available in the marketplace. When these generic drugs became available, we began covering them at the
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective July 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More information2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
207 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Plus Plan (HMO) H5087-002, H5087-07 This is a listing of the changes that have occurred in our formulary.
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective January 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More information2017 Formulary Addendum Notice of Change (Medicare Advantage Plans)
2017 Formulary Addendum Notice of Change (Medicare Advantage Plans) Easy Choice Health Plan Easy Choice Best Plan (HMO) H5087-005 This is a listing of the changes that have occurred in our formulary. Please
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective July 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More informationRelative Cost/Month. Less than $10. Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
Allergy Chlorpheniramine Tablet* Diphenhydramine Tablet* Diphenhydramine Liquid* Loratadine Tablet* Cetirizine Tablet* Loratadine 10mg ODT* Less than $10 Loratadine Liquid* $10-$15 Cetirizine liquid 1mg/mL*
More informationPharmacy Updates Summary
All of the following changes were reviewed and approved by the SFHP Pharmacy & Therapeutics (P&T) Committee on 4/16/2014 Effective date: 5/15/2014 Therapeutic Classes reviewed: ADHD Ophthalmic antihistamines
More informationThe Weekly Mortar & Pestle
The Weekly Mortar & Pestle A Publication of Walgreens Health Initiatives The accuracy and completeness of the content herein are not guaranteed by Walgreen Co. or its affiliates and subsidiaries. Content
More informationAlameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee Decisions
Alameda Alliance for Health FORMULARY UPDATE Effective: October 27, 2017. Drugs notated with an * have an undetermined implementation date Alameda Alliance for Health Pharmacy & Therapeutics (P&T) Committee
More informationHealth Partners Medicare Special (2017) Updates
March 2017 Effective Date Brand Name EVZIO erythromycin ethylsuccinate naloxone hcl Generic Name erythromycin ethylsuccinate Type of Change Previous Value New Value ofloxacin ofloxacin NAMZARIC NAMZARIC
More informationAdvanced Control Formulary Change Summary Report Effective
This report highlights all changes (additions, deletions, and removals) to the CVS Caremark Advanced Control Formulary ADDITIONS: Brand Agents: Austedo (deutetrabenazine) tablet Cystagon (cysteamine bitartrate)
More informationMarch 2017 Pharmacy & Therapeutics Committee Decisions
UCare s Pharmacy and Therapeutics Committee (P&T) is a group of physicians and pharmacists that meet throughout the year to make changes to the UCare formulary (approved drug list). These changes are reviewed
More informationDrug Formulary Update, July 2016 Commercial and State Programs
Drug Formulary Update, July 2016 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More informationQuarterly pharmacy formulary change notice
Provider update Quarterly pharmacy formulary change notice Summary: The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018, Pharmacy and Therapeutics Committee
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Methylphenidates Page: 1 of 7 Last Review Date: November 30, 2018 Methylphenidate Dexmethylphenidate
More informationUpdates to your prescription benefits
Updates to your prescription benefits Effective Jan. 1, 2018 Update Summary Within the Prescription Drug List (PDL), medications are grouped by tier. The tier indicates the amount you pay when you fill
More information2015 Step Therapy Prior Authorization Medical Necessity Guidelines
Tufts Health Unify 2015 Step Therapy Prior Authorization Medical Necessity Guidelines Effective: 01/01/2015 Updated: 10/01/2015 Tufts Health Plan P.O. Box 9194 Watertown, MA 02471-9194 Phone: 855-393-3154
More information2018 Formulary Update
MEDICARE ADVANTAGE BlueShield of Northeastern New York 2018 Formulary Update BlueShield of Northeastern New York has updated its formulary (drug list) since its original publication in January 2018. This
More informationUS pharmaceutical market: trends, issues, forecast. Doug Long Vice President Industry Relations IMS Health
US pharmaceutical market: trends, issues, forecast Doug Long Vice President Industry Relations IMS Health 2006 Strategic management review The World Pharmaceutical Market All reproduction rights, quotations,
More informationMethylphenidate Dexmethylphenidate
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.60.25 Yeah Subject: Methylphenidates Page: 1 of 6 Last Review Date: September 15, 2017 Methylphenidate
More informationCentral Nervous System Stimulants Drug Class Prior Authorization Protocol
Line of Business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Central Nervous System Stimulants Drug Class Prior Authorization Protocol This policy has been developed through
More informationFDA Approval LIST. WellINFORMED. Generic Name(s) Brand Name (manufacturer) Therapeutic Use. Brief Description. Potential Impact.
FDA Approval LIST Formulary management is one way to bring down drug costs, and deciding which medications to include on a formulary is part of this process. New drug releases are generally associated
More informationQuarterly pharmacy formulary change notice
Quarterly pharmacy formulary change notice Provider update Summary: Effective August 1, 2018, the preferred formulary changes detailed in the table below will apply to District of Columbia Healthy Families
More informationALOGLIPTIN STEP. Details. Step Therapy Requirements Effective November 1, 2017
ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone 15 mg tablet alogliptin 12.5 mg-pioglitazone
More informationANTICONVULSANTS. Details
ANTICONVULSANTS Aptiom 200 mg tablet Aptiom 400 mg tablet Aptiom 600 mg tablet Aptiom 800 mg tablet Banzel 200 mg tablet Banzel 40 mg/ml oral suspension Banzel 400 mg tablet Fycompa 0.5 mg/ml oral suspension
More informationBLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES
BLUE SHIELD OF CALIFORNIA JUNE 2016 PLUS DRUG FORMULARY CHANGES Blue Shield is committed to covering safe, effective and affordable medications, so we regularly review and update our drug formularies.
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs. Program Number 2017 P Prior Authorization/Notification CNS Stimulants
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 1020-6 Program Prior Authorization/Notification CNS Stimulants Medication Adderall* (amphetamine-dextroamphetamine mixed salts),
More informationHEALTH SHARE/PROVIDENCE (OHP)
HEALTH SHARE/PROVIDENCE (OHP) STEP THERAPY This is a complete list of drugs that have written coverage determination policies. Drugs on this list do not indicate that this particular drug will be covered
More informationAlprazolam 0.25mg, 0.5mg, 1mg tablets
Presbyterian Senior Care (HMO) / Presbyterian MediCare PPO Quantity Limits Effective November 1, 2014 For the most recent list of drugs or other questions, please contact the Presbyterian Customer Service
More informationQuarterly pharmacy formulary change
Medi-Cal Managed Care L. A. Care Major Risk Medical Insurance Program Provider Bulletin The formulary changes listed in the table below were reviewed and approved at our first-quarter 2018 Pharmacy and
More informationYour prescription benefit updates Formulary Updates - Effective January 1, 2019
Your prescription benefit updates Formulary Updates - Effective January 1, 2019 Medications are grouped by the conditions they treat. Each medication is placed in a tier that shows the amount you will
More informationOregon Health Plan prescription benefit updates
Oregon Health Plan prescription benefit updates EOCCO s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps you save
More information2014 DTC National Advertising Awards Finalists
2014 DTC National Advertising Awards Finalists All Gold, Silver, and Bronze winners will be announced at the DTC National Advertising Awards Dinner on April 23. Each therapeutic category winner from Television,
More informationOVERVIEW FOOD AND DRUG ADMINISTRATION-APPROVED INDICATIONS
Pharmacy Medical Necessity Guidelines: Effective: September 18, 2017 Prior Authorization Required Type of Review Care Management Not Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select April 1, 2018 Updates Drug Name adapalene-benzoyl-peroxide Gel 0.1-2.5% (Brand = Epiduo ) prasugrel hcl (Brand = Effient ) vigabatrin pak 500 mg (Brand
More informationPharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications
Pharmacy Medical Necessity Guidelines: ADHD CNS Stimulant Medications Effective: November 13, 2018 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review
More informationDrug Formulary Update, April 2017 Commercial and State Programs
Drug Formulary Update, April 2017 Commercial and State Programs Updates to the HealthPartners Commercial and State Program Drug Formularies are listed below. Updates apply to all Commercial groups (PreferredRx,
More information2017 Formulary Changes Year to Date
2017 Formulary Changes Year to Date Health Choice Arizona may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, add prior authorization, quantity limits and/or
More informationBlueLink TPA FlexRx Updates
BlueLink TPA FlexRx Updates April 2018 TRADE NAME (generic name) or generic name abacavir sulfate soln 20 mg/ml (base equiv) Generic Addition, generic for ZIAGEN alclometasone dipropionate cream 0.05%
More informationALOGLIPTIN STEP. Step Therapy Requirements Effective April 1, 2018
Step Therapy Requirements Effective April 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone
More informationMedicare Part D 2017 Formulary Changes OC Preferred
Medicare Part D 2017 Formulary Changes OC Preferred Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
More informationALOGLIPTIN STEP. Step Therapy Requirements Effective June 1, 2018
Step Therapy Requirements Effective June 1, 2018 ALOGLIPTIN STEP alogliptin 12.5 mg tablet alogliptin 12.5 mg-metformin 1,000 mg tablet alogliptin 12.5 mg-metformin 500 mg tablet alogliptin 12.5 mg-pioglitazone
More informationMedimetriks Highlights
Medimetriks Highlights Specialty pharma company targeting medical Dermatology Established commercial operations with a Sales Force approaching 40 strong in key US markets Marketed brands for treatment
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary April 1, 2018 Updates. Formulary Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select April 1, 2018 Updates Drug Name adapalene-benzoyl-peroxide Gel 0.1-2.5% (Brand = Epiduo ) prasugrel hcl (Brand = Effient ) vigabatrin pak 500 mg (Brand
More informationICP Formulary Updates
ICP Formulary Updates July 2017 TRADE NAME (generic name) adapalene cream 0.1% 2017-07-01 Removal adapalene gel 0.3% 2017-07-01 Removal adefovir dipivoxil tab 10 mg 2017-07-01 Removal ADVAIR DISKUS (fluticasone-salmeterol
More informationMedicare Part D 2017 Formulary Changes Service To Senior
Medicare Part D 2017 Formulary Changes Service To Senior Inter Valley Health Plan may add or remove drugs from our formulary during the year. If we remove a drug from our formulary, add prior authorization,
More informationPharmacy Benefit Management (PBM) Program FORMULARY/PRODUCT RESTRICTIONS
Workforce Safety & Insurance Revised Document Date: 07/23/2015 1600 E Century Ave Ste 1 PO Box 5585 Bismarck, ND 58506-5585 701.328.3800 1.800.777.5033 www.workforcesafety.com Pharmacy Benefit Management
More informationChanges to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies
Changes to the 2018 BlueCross Secure SM (HMO) & BlueCross Total SM (PPO) Formularies BlueCross BlueShield of South Carolina may add or remove drugs from the formulary during the year. If we remove drugs
More information2017 Medicare Part D Formulary Change
2017 Medicare Part D Formulary Change We may add or remove drugs from our formulary during the year. If we remove drugs from our formulary, or add prior authorizations, quantity limits and/or step therapy
More informationKentucky Department for Medicaid Services Drug Review and Options for Consideration
Drug Review and The following table lists the Agenda items scheduled, as well as the, to be presented and reviewed at the March 16, 2017 meeting of the Pharmacy and Therapeutics Advisory Committee. Single
More informationNew Product to Market: Trelegy Ellipta Magellan Health, Inc. All rights reserved.
Drug Review and The following tables list the Agenda items as well as the that are scheduled to be presented and reviewed at the March 15, 2018 meeting of the Pharmacy and Therapeutics Advisory Committee.
More information2018 Step Therapy FID 18088
2018 Step Therapy FID 18088 Step Therapy ANTIDEPRESSANTS, SEROTONIN/NOREPINEPHRINE REUPTAKE INHIBITORS LEON 2018 Desvenlafaxine Er Fetzima Fetzima Titration Pack Khedezla Paxil SUSP Pristiq Trintellix
More informationStep Therapy Requirements. Effective: 11/01/2018
Effective: 11/01/2018 Updated 10/2018 ANTIDEPRESSANTS Sharp Health Plan (HMO) TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK
More informationAPREPITANT ARMODAFINIL BELSOMRA BUPAP BUPRENORPHINE HCL BUTALBITAL-ACETAMINOPHEN BUTALBITAL-APAP-CAFF-COD BUTALBITAL-APAP-CAFFEINE
APREPITANT Aprepitant Oral Capsule 125, 40, 80 Aprepitant Oral Capsule 80 & 125 Quantity Limit: 8 EA Per 30 Days Quantity Limit: 12 EA Per 30 Days ARMODAFINIL Armodafinil Oral Tablet 150, 200, 250, 50
More informationNew Mexico Health Connections Drug Safety Updates Q4 2018
Dupixent dupilumab Moderate-to-severe atopic dermatitis, Moderate-to-Severe asthma SQ Injection On October 19, 2018, new warnings were added to the Dupixent drug label regarding judicious use in eosinophilic
More informationStep Therapy Requirements. Effective: 05/01/2018
Step Therapy Requirements Effective: 05/01/2018 ANTIDEPRESSANTS TRINTELLIX 10 MG TABLET TRINTELLIX 20 MG TABLET TRINTELLIX 5 MG TABLET VIIBRYD 10 MG (7)-20 MG (23) TABLETS IN A DOSE PACK VIIBRYD 10 MG
More informationFARXIGA (dapagliflozin) Jardiance (empagliflozin) tablets. Synjardy (empagliflozin and metformin hydrochloride) tablets. GLUCOPHAGE* (metformin)
Type 2 Medications Drug Class How It Works Brand and Generic Names Manufacturers Usual Starting Dose The kidneys filter sugar and either absorb it back into your body for energy or remove it through your
More informationPrescription benefit updates Individual/small group
Prescription benefit updates Individual/small group Moda Health s prescription program is a pharmacy benefit that offers members a choice of safe and effective medication treatments. The program also helps
More informationStep Therapy Medications
Step Therapy Medications Step Therapy (ST PA ) is an automated form of prior authorization. It encourages the use of therapies that should be tried first, before other treatments are covered, based on
More informationPharmacy Prep. Qualifying Pharmacy Review
Pharmacy Prep 2014 Misbah Biabani, Ph.D Director, Tips Review Centres 5460 Yonge St. Suites 209 & 210 Toronto ON M2N 6K7, Canada Luay Petros, R.Ph Pharmacy Manager, Wal-Mart, Canada 1 Disclaimer Your use
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationClinical Policy: CNS Stimulants Reference Number: CP.PMN.XX Effective Date: Last Review Date: Line of Business: Commercial, Medicaid
Clinical Policy: Reference Number: CP.PMN.XX Effective Date: 03.01.18 Last Review Date: 02.18 Line of Business: Commercial, Medicaid Revision Log See Important Reminder at the end of this policy for important
More informationANTICONVULSANTS. Details
ANTICONVULSANTS APTIOM 200 MG APTIOM 400 MG APTIOM 600 MG APTIOM 800 MG BANZEL 200 MG BANZEL 40 MG/ML ORAL SUSPENSION BANZEL 400 MG FYCOMPA 0.5 MG/ML ORAL SUSPENSION FYCOMPA 10 MG FYCOMPA 12 MG FYCOMPA
More informationStep Therapy Requirements. Effective: 1/1/2019
Effective: 1/1/2019 Updated 1/2019 AMANTADINE ER Sharp Health Plan (HMO) OSMOLEX ER 129 MG, EXTENDED RELEASE OSMOLEX ER 193 MG, EXTENDED RELEASE OSMOLEX ER 258 MG, EXTENDED RELEASE PRIOR CLAIM FOR AMANTADINE
More informationAMANTADINE ER. Products Affected Step 2: OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, Details
AMANTADINE ER OSMOLEX ER 129 MG TABLET, EXTENDED RELEASE OSMOLEX ER 193 MG TABLET, EXTENDED RELEASE OSMOLEX ER 258 MG TABLET, PRIOR CLAIM FOR AMANTADINE HCL IMMEDIATE RELEASE WITHIN THE PAST 120 DAYS.
More informationNEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16
New Medicine Product/Device Endorsement Categories NEW MEDICINE APPLICATIONS BROUGHT TO THE BORDERS FORMULARY COMMITTEE (BFC) AND AREA DRUG & THERAPEUTICS COMMITTEE (ADTC) 2015/16 A B C D E F recommended
More information2018 Formulary Notice of Change Prescription Drug Plans
2018 Formulary Notice of Change Prescription Drug Plans WellCare Prescription Insurance, Inc. Plans in all states: WellCare Classic (PDP) WellCare may add or remove drugs from our formulary during the
More informationAdditional Drug Coverage
Additional Drug Coverage Additional prescription drug coverage Your plan includes extra coverage for certain drugs and supplies as shown below. These drugs are either not generally covered under Medicare
More informationAdditional DRUG COVERAGE
Additional DRUG COVERAGE Additional prescription drug coverage Your plan includes extra coverage for certain drugs as shown below. These drugs are either not generally covered under Medicare Part D or
More informationADHD Stimulant Step Therapy Program
ADHD Stimulant Step Therapy Program Policy Number: 5.01.592 Last Review: 7/2018 Origination: 7/2017 Next Review: 7/2019 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage
More informationANTIDEPRESSANTS. Details. dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet. Criteria
ANTIDEPRESSANTS Trintellix 10 mg tablet Trintellix 20 mg tablet Trintellix 5 mg tablet Viibryd 10 mg (7)-20 mg (23) tablets in a dose pack Viibryd 10 mg tablet Viibryd 20 mg tablet Viibryd 40 mg tablet
More information2018 CareOregon Advantage Part D Formulary Changes
2018 CareOregon Advantage Part D Formulary Changes Abbreviations: AGE = Age Restriction; PA = Prior Authorization Required; QL = Quantity Limit; ST = Step Therapy Required; LD = Limited Distribution; BvD
More information